US dosage forms specialist expands its capabilities and technologies
Capsugel is to expand its capabilities with the purchase of Xcelience and Powdersize.
Terms of the transactions have not been disclosed, but Capsugel said the addition of the two firms would further enhance its position as a leading provider of dosage forms and solutions.
Tampa, Florida, US-based Xcelience provides Capsugel with specialised clinical trial manufacturing, labelling and distribution capabilities for a broad range of solid dosage forms.
Quakertown, PA-based Powdersize brings micronisation capabilities that augment Capsugel’s formulation design services and bioavailability enhancement technology platform.
'The additions of Xcelience and Powdersize accelerate Capsugel's strategy to expand our service offerings through continued investments in new capabilities and technologies,' said Guido Driesen, President and CEO of Capsugel.
'The expertise and high levels of service that we gain in this transaction will make us an even stronger, more-differentiated partner as we collaborate with pharmaceutical companies to bring better medicines to patients.'
Capsugel also gains specialised commercial manufacturing capabilities and a pipeline of customer product programmes that complement its pipeline of early- and late-stage customer projects in areas such as speciality therapeutics and orphan disease.
The firm is also adding infrastructure for the handling of highly potent and controlled substances, complementing Capsugel's existing specialised handling capabilities at its pharmaceutical dosage-form sites in the US, France, and the UK.
'We are ready to take Xcelience to the next level, and Capsugel’s global scale, commitment to science and engineering, and technology breadth and depth make it the right partner to get us there,' said Derek Hennecke, President and CEO of Xcelience.
'Our collective customers will have access to a robust suite of design and development capabilities, as well as best-in-class clinical supply solutions and commercial manufacturing of innovative dosage forms.'
Wayne Sigler, CEO of Powdersize, said: 'We are thrilled to join forces with Capsugel. Our capabilities in particle-size reduction are a natural fit with Capsugel’s bioavailability enhancement suite of technologies and services. Our clients will benefit from the capabilities that the combined entity can now offer.'
Once the deal is complete, both Xcelience and Powdersize will be integrated with Capsugel’s Dosage Form Solutions business unit, which offers bioavailability enhancement, a complete range of modified release solutions and a growing suite of applications in other areas, including bio-therapeutics, inhalation and paediatric formulations.